Is United Health Stock Still Undervalued? | UNH Stock Analysis

SUMMARY

Parkev Tatevosian, CFA, provides an in-depth analysis of UnitedHealth Group's recent performance, focusing on revenue growth, profitability, and valuation. He discusses management's strategic adjustments, the impact of government contracts on margins, and reaffirms his buy rating for the stock.

MAIN POINTS

• UnitedHealth stock has risen over 22% year to date in 2026 but is experiencing a recent dip after peaking near $440 per share. [0:00]
• The company restricted product categories and geographies in response to underestimated costs, leading to slower revenue growth. [1:00]
• Operating profit margins collapsed from over 8% to around 4% in 2025 due to cost miscalculations but have rebounded in 2026 after management adjustments. [2:01]
• Returns on invested capital mirrored the margin decline and recovery, reflecting the company's profitability challenges and improvements. [3:00]
• Reliance on government contracts provides stability but limits profit margins, a trend seen across similar industries like defense contracting. [4:00]
• The stock remains undervalued with a forward P/E of 18 and a fair value estimate of $473, leading to a reiterated buy rating. [5:02]

DETAILED ANALYSIS

UnitedHealth Group has demonstrated robust share price performance in 2026, with gains exceeding 22% year to date, despite a recent pullback from its peak. Over the past decade, the company achieved significant revenue growth, rising from approximately $180 billion in 2017 to $450 billion in the trailing twelve months. However, recent quarters have seen a deceleration in revenue expansion, driven by management's strategic decision to limit product offerings and geographic reach.

This move was prompted by a realization in 2025 that the company had underestimated the cost of serving certain customer segments, making continued service in those areas unprofitable without substantial price increases. Rather than risk losing market share through aggressive pricing, UnitedHealth opted to scale back its exposure in less profitable categories.

These adjustments have already begun to yield positive results, as evidenced by a rebound in operating profit margins. After a sharp decline from over 8% to around 4% in 2025 due to soaring costs and the inability to adjust pricing midyear, margins have improved in 2026 following policy and pricing changes. A similar pattern is observed in the company's returns on invested capital, which recovered after a significant drop last year.

Despite these improvements, UnitedHealth's profitability remains constrained by its reliance on government contracts, a characteristic shared with other sectors such as defense contracting. Government partnerships provide revenue stability and insulation from broader economic cycles but inherently cap profit margins, making double-digit operating margins unlikely.

From a valuation standpoint, UnitedHealth's forward price-to-earnings ratio stands at 18, near the lower end of its historical range. The fair value estimate is calculated at $473 per share, compared to a current market price of $440, suggesting the stock remains undervalued. Given the company's demonstrated ability to adapt to cost pressures and maintain stable, if modest, profitability, the long-term outlook remains positive.

The analysis concludes with a reaffirmed buy rating, reflecting both the attractive valuation and the company's resilience in a challenging operating environment.

LINKS

• Membership page for exclusive channel perks and resources.
• Special Motley Fool Stock Advisor offer for viewers.
• Purchase Parkev Tatevosian's book on stock investing frameworks.
• Discounted access to Fiscal.ai investment research tools.
• Sign up for Webull and receive bonus shares.
• Subscribe to Parkev Tatevosian's free monthly Substack newsletter.

KEYWORDS